- Prev close
- $130.86
- Day range
- $130.59 – $134.09
- Next earnings
- in 81 days
Gilead rose +0.7% in a strong tape, helped by a court win and an earnings window, but the move is modest against an after-hours report date and sits alongside a mixed near-term trend.
GILD
GILEAD SCIENCES INC
As of Aug 4, 2026
68/100
Worth keeping an eye onHealth ScoreMove drivers
GILD gained +0.7% while the S&P 500 rose +1.8% and the Nasdaq 100 rose +3.4%, so the broader market was supportive but not enough to explain the stock on its own. Same-day peers were weaker, with ABBV -0.5% and AMGN -1.6%, which makes GILD’s strength look more stock-specific than sector-wide. The cleanest primary driver is company-specific news: Reuters reported that California’s highest court ruled in favor of Gilead in the 'duty to innovate' case involving HIV drugs, a concrete legal positive that fits the outperformance versus peers.
Volatility check
This looks like ordinary-to-moderate volatility for a defensive large-cap, not a sign of deteriorating fundamentals. The business still shows revenue +3.5% YoY (TTM), latest quarter +4.4% YoY, and EPS +55.5% YoY (TTM), with gross margin +79.3%, operating margin +34.9%, and net margin +31.0%. Valuation is not cheap at PE 17.7, forward PE 25.3, and PEG 2.53 — the PEG, or P/E divided by growth rate, means investors are paying more than 2.5x the growth rate, so good news can already be partly priced in. Beta is 0.33, which usually points to lower day-to-day swings, so a +0.7% move on legal and earnings catalysts is not out of character, but it is also not a runaway reaction.
Earnings preview
The next earnings date is 2026-08-04, and the market is already framing the print as a tight event window; options pricing cited a 5.15% move for Gilead. The facts here do not include consensus revenue or EPS estimates for the upcoming quarter, so I cannot quote expected growth or margin targets this period. What the market is waiting to learn is whether revenue growth can extend beyond the recent +4.4% YoY quarterly pace, whether EPS momentum can stay near the +55.5% YoY TTM rate, and how management discusses durability after the legal win in the 'duty to innovate' case. No prior post-earnings reaction data is provided in the facts, so I won’t infer a pattern from past prints.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track GILD with WhyIHold
Get a plain-English explanation the next time GILEAD SCIENCES INC makes a big move — so you know whether it's benign or worth your attention.